Trial
NCT05256381
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
SOTIO Biotech AG
Collaborators
Merck Sharp & Dohme LLC
Condition
Non-Small Cell Lung Cancer
Intervention
Nanrilkefusp Alfa
Why stopped
Due to lack of expected efficacy shown at the time of the interim analysis
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-17